Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLU4 | ISIN: US14070B3096 | Ticker-Symbol: 4LN2
Tradegate
27.06.25 | 18:53
9,560 Euro
+0,10 % +0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAPRICOR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CAPRICOR THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,3009,58027.06.
9,4309,67027.06.

Aktuelle News zur CAPRICOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoB.Riley initiates Capricor Therapeutics stock with buy rating8
DoB.Riley startet Bewertung von Capricor Therapeutics mit Kaufempfehlung9
DiFDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy15
DiCapricor stock rating reiterated at Overweight by Cantor Fitzgerald14
MoWhy Is Capricor Therapeutics Stock Trading Lower On Monday?10
CAPRICOR Aktie jetzt für 0€ handeln
MoH.C. Wainwright reaffirms Capricor Therapeutics stock rating amid FDA changes8
MoCapricor stock price target cut by Oppenheimer on FDA review concerns26
20.06.Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients8
20.06.Capricor falls after long-term trial data for Duchenne therapy11
20.06.Capricor Therapeutics-Aktie stürzt nach Beurlaubung wichtiger FDA-Beamter ab18
20.06.Capricor Therapeutics stock plunges after key FDA officials placed on leave5
20.06.Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy162Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow with extended treatment (PUL v2.0)Deramiocel's long-term safety profile remains...
► Artikel lesen
17.06.Capricor gets FDA's Orphan Drug status for muscle disorder therapy9
17.06.Capricor Says FDA Grants Orphan Drug Designation For Deramiocel To Treat Becker Muscular Dystrophy7
17.06.Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program19
16.06.CAPRICOR THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
16.06.H.C. Wainwright reaffirms Capricor stock rating amid FDA meeting notice withdrawal8
11.06.Capricor falls after facility inspection related to deramiocel6
11.06.Capricor Therapeutics stock falls after FDA inspection of manufacturing facility8
11.06.Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program233U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensureAdvisory Committee meeting scheduled for July 30, 2025Mid-cycle meeting...
► Artikel lesen
Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1